Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6)

Diabetes Res Clin Pract. 2008 Aug;81(2):e1-3. doi: 10.1016/j.diabres.2008.03.021. Epub 2008 May 16.

Abstract

Intensive insulin therapy composed of bolus and basal insulin has been believed as the most powerful recipe for glycemic control of both type 1 and type 2 diabetes. In this study, we investigated the effects of changes in basal/total daily insulin ratio (B/TD ratio) in type 2 diabetes patients on intensive insulin therapy including insulin glargine. The B/TD ratio used in our Japanese patients was about 0.35, and the ratio was increased up to about 0.46+/-0.12 without change of total insulin daily dose. After 24-week-treatment, mean glycated albumin of the patients whose B/TD ratio was increased was significantly lower than those of the patients whose B/TD ratio was not changed. Our results suggest that adequate supplementation of basal insulin may be important for maximum effect of bolus insulin even in Japanese who have serious defect in postprandial rapid insulin secretion.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Glycated Serum Albumin
  • Glycation End Products, Advanced
  • Glycosylation
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use
  • Insulin / administration & dosage
  • Insulin / analogs & derivatives*
  • Insulin / therapeutic use*
  • Insulin Glargine
  • Insulin, Isophane / therapeutic use
  • Insulin, Long-Acting
  • Serum Albumin / metabolism

Substances

  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Serum Albumin
  • Insulin Glargine
  • Insulin, Isophane
  • Glycated Serum Albumin